52 drugs are out of supply nationwide.

1, pharmaceutical enterprises commitment: the national unified suspension of supply on October 16, Inner Mongolia Pharmaceutical Mining Center issued "on the cancellation of Heilongjiang Province Jiren Pharmaceutical Co., Ltd. and other enterprises produced part of the drug registration network qualification notice."
the notice, 24 pharmaceutical companies applied to disqualify the drug network, and submitted a unified national commitment not to supply, involving a total of 52 drugs.
25 of them are Chinese medicine, 27 are chemicals, most of them are low-cost drugs, cheap drugs.
from the contents of the notice, the 52 drugs applied for a nationwide suspension of supply, including production line rectification and upgrading, production stoppage and so on.
this is not the first time this year that Inner Mongolia has issued a similar announcement.
As early as July 2, the Inner Mongolia Pharmaceutical Harvesting Center issued a notice that: from March 1 to June 30, 2020, due to rising raw materials, production line transformation, drug approval was withdrawn and other reasons led to the cessation of production of many drugs, 20 pharmaceutical companies to Inner Mongolia to apply for the disqualification of 40 drugs, and submitted a unified national non-supply commitment letter.
In fact, we are no strangers to drug companies taking the initiative to cancel the qualification of hanging up the network, and even committed to national unity of non-supply initiatives, which in recent years, drug recruitment in various places have occurred from time to time.
September 14, Guizhou Provincial Public Resources Trading Center issued a notice that 22 drugs to cancel some of the drug winning bid (hanging net) qualification, because some enterprises due to production line transformation, production stoppage and other reasons, drugs have been unable to guarantee supply.
shall not participate in the centralized procurement of drugs in Guizhou Province for two years in accordance with the regulations.
July 22, Ningxia Public Resources Trading Service Center issued a notice that 103 pharmaceutical companies have submitted applications for scrapping (revoking) of drugs, involving a total of 261 drugs.
May 21, Shanxi Province drug bidding procurement network issued two active withdrawal notice, involving a total of 66 drugs.
in addition to the drug in Shanxi to revoke the registration of the network, the relevant pharmaceutical companies have also provided a "national unified commitment not to supply."
2, the main reason for rising costs is from the announcement issued around, pharmaceutical companies choose the national unity of non-supply is mainly due to production, and most pharmaceutical companies stop production is the main reason for rising costs.
to the rise in raw material prices, we should feel deeply.
in recent years, the price of some RAW drugs has risen by an astonishing amount.
For example, in 2019, the State Administration of Market Supervision received reports that pharmaceutical distribution companies had a monopoly on the injection of calcium glucosate API, resulting in a shortage of calcium glucosate injections and a sharp increase in prices.
2017 sales of calcium glucosate raw materials increased 19 times to 54.6 times compared to 2014 prices.
earlier, Malay acid chlorobenamine rose 58 times in a month from 400 yuan/kg to 23,300 yuan/kg, and phenol rose 99 times from 230 yuan/kg to 23,000 yuan/kg. In addition to rising raw material costs, which have companies' costs soaring, there are environmentally friendly inputs.
since the introduction of the environmental tax, atmospheric and water pollutant discharge enterprises have been the most affected.
industry analysis, the current domestic pharmaceutical enterprises of a certain size, if calculated in accordance with the environmental tax law, sewage treatment costs alone will be hundreds of millions of yuan, and, not including exhaust gas, solid waste and so on.
it is understood that, as the only life-saving drug for patients with hepatic bean-shaped nuclear degeneration,sodium propylene injection has also been discontinued this year.
since it was out of stock in March this year, it is still hard to find medicine.
, according to people familiar with the matter, the shortage of the drug is mainly due to environmentally friendly relocation and process improvements.
for Chinese medicine, tighter regulation is also a major factor affecting rising costs.
With the implementation of the newly revised Drug Administration Law, the 2020 edition of the Pharmacopeia will also be implemented from December 30 this year, coupled with the traceability of Chinese medicine, Chinese herbal medicine and its beverage tablet products continue to increase the number of heavy metals and 33 agricultural residues testing to become a reality must face the problem.
Under strict requirements, upstream enterprises need to upgrade the production software hardware, downstream production enterprises are afraid to use those poor, content is not up to standard, agricultural residues exceed the standard varieties, but at present, the market is high-quality varieties or limited, in the supply and demand imbalance, those high quality, high standards of Chinese herbal raw materials, the next may face price increases.
will also face rising costs for drinking tablets and Chinese medicine companies.
it is well known that if pharmaceutical production does not meet the expected profit margins, it may lead to two situations, either the price of the product to maintain production, or stop production.
from the root, balance the relationship between the profits of enterprises and clinical needs, is the next relevant departments and enterprises need to think deeply about the problem.
: Inner Mongolia cancels the list of listed varieties.